anti-tau antibody
By developing a full-length humanized monoclonal IgG1 antibody that specifically binds to human tau, the problem of poor efficacy of existing anti-tau antibody therapies in the treatment of Alzheimer's disease has been solved, and the effective inhibition and slowing of tau pathology in mouse models has been achieved.
Patent Information
- Application Number
- CN202580026987.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-16
- Filing Date
- 2025-03-12
- Publication Date
- 2026-11-17
AI Technical Summary
Existing anti-tau antibody therapies have failed to effectively slow the rate of tau accumulation or clinical decline in the brains of Alzheimer's patients, and there is still a need to develop novel anti-tau antibodies to treat neurodegenerative diseases such as Alzheimer's disease.
A full-length humanized monoclonal IgG1 antibody that specifically binds to human tau, particularly an antibody that selectively binds to hyperphosphorylated T231 (pT231), comprising specific CDR-H1, CDR-H2, CDR-H3 and CDR-L1, CDR-L2, CDR-L3, and a variable region amino acid sequence, is provided for inhibiting or delaying the spread of tau pathology between neurons.
This antibody significantly reduced the spread of tau pathology in mouse models, decreased the percentage of tau neurons aggregated in the hippocampus and medial thalamus, and delayed the spread of tau pathology.
Smart Images

Figure CN123125231A_ABST
Abstract
Description
References to sequence lists
[0001] This application includes a sequence list submitted electronically in the form of an XML file named ABV21639USO1_ST26.xml, which was created on February 14, 2025, and has a size of 19,848 bytes. This sequence list is incorporated herein by reference. Background Technology
[0002] Tau is a neuronal microtubule-associated protein primarily found in axons, and its function is to promote microtubule polymerization and stabilize microtubules. Tau's physiological function is highly regulated by a series of post-translational modifications, including phosphorylation, acetylation, glycosylation, isomerization, nitration, SUMOylation, and ubiquitination. Alterations in these modifications can affect tau function and potentially lead to pathological conditions. Deposition of abnormal tau proteins in the brain is associated with a group of neurodegenerative disorders collectively known as "tau proteinopathy," which includes Alzheimer's disease.
[0003] Alzheimer's disease is the most common cause of dementia in the elderly; in 2020, approximately 50,000,000 people worldwide had dementia, with 60% to 70% of dementia cases attributed to AD. By 2050, the number of dementia cases worldwide is expected to increase to over 150,000,000. Recent evidence has shown that the onset of AD may begin years before any signs of the disease become noticeable; by the time patients notice cognitive impairment, the cascade of events leading to full-blown AD may be irreversible without disease-modifying therapies.
[0004] Hyperphosphorylated tau (pathological tau) is a major component of neurofibrillary tangles (NFTs), a characteristic pathological feature of Alzheimer's disease (AD). Pathologically, AD is defined as extracellular accumulation of Aβ plaques, intracellular accumulation of tau, neuroinflammation, neuronal and synaptic loss, and severe brain atrophy. Tau deposits in the brain are associated with memory decline, confirming the importance of tau pathology in AD. See Braak et al., “Neuropathological staging of Alzheimer-related changes,” Acta Neuropathol. 1991; 82:239-59; Nelson et al., “Correlation of Alzheimer Disease Neuropathologic changes with Cognitive Status: A Review of the Literature,” J. Neuropathol. Exp. Neurol. 2012; 72:362-81.
[0005] In Alzheimer's disease, tau pathology spreads along neural networks in a stereotyped pattern from one region of the brain to another in a "prion-like" manner. NFTs appear in the entorhinal cortex and spread via the hippocampus to anatomically connected areas across the entire cerebral cortex. See Braak, ibid. The progression of cognitive impairment is closely associated with tau pathology, as assessed by markers such as aggregation or hyperphosphorylation. See Braak et al., "Staging of Alzheimer's disease-associated neurofibrillary pathology using paraffin sections and immunohistochemistry," Acta Neuropathol. 2006; 112:389-404; Braak et al., "Neuropathological staging of Alzheimer's-related changes," Acta Neuropathol. 1991; 82:239-59.
[0006] Anti-tau antibodies and vaccines have been evaluated in preclinical studies, and at least eleven anti-tau antibodies have reached clinical trials for the treatment of Alzheimer's disease. See, for example, Guo et al., “Tau-targeting therapy in Alzheimer's disease: critical advances and future opportunities”, Ageing NeurDis 2022; 2:11; Panza et al., “The challenges of anti-tau therapeutics in Alzheimer's Disease” Nature Reviews Neurology 18, 577-78 (2022); Jadhav et al., “A Walk Through Tau Therapeutic Strategies,” Acta Neuropathologica Communications, 22 (2019). However, no anti-tau therapy has been approved. A phase 2 study of the monoclonal anti-tau antibody semorinemab found that semorinemab did not slow the rate of tau accumulation or clinical decline in the brains of patients with pre- or mild Alzheimer's disease. Teng et al., “Safety and Efficacy in Individuals with Prodromal to Mild Alzheimer's Disease: A Randomized Clinical Trial,” JAMA Neurol.2022; 79(8):758-767. Another monoclonal antibody targeting the N-terminal region of tau, gosuranemab, did not produce clinical benefit in participants with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease. Shulman et al., “Top-line results from TANGO, a phase 2 study of gosuranemab in participants with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease,” J Prev Alzheimers Dis.2021; 8 (Supplement 1):S65. The anti-tau antibody zagotenemab was discontinued after its phase II study in Alzheimer's disease failed.See Muller, “Anti-tau antibody failures stack up,” Nature Reviews DrugDiscovery 20, 888 (2021).
[0007] There is still a need for novel anti-tau antibodies to treat neurodegenerative diseases such as Alzheimer's disease. Summary of the Invention
[0008] This disclosure provides antibodies that specifically bind to human tau, particularly antibodies that selectively bind to hyperphosphorylated T231 (pT231).
[0009] In its implementation, this disclosure provides a full-length anti-tau antibody comprising a heavy chain variable region containing CDR-H1, CDR-H2, and CDR-H3, and a light chain variable region containing CDR-L1, CDR-L2, and CDR-L3, wherein:
[0010] vH CDR-H1 has the amino acid sequence shown in SEQ ID NO: 3;
[0011] vH CDR-H2 has the amino acid sequence shown in SEQ ID NO: 4;
[0012] vH CDR-H3 has the amino acid sequence shown in SEQ ID NO: 5;
[0013] vL CDR-L1 has the amino acid sequence shown in SEQ ID NO: 8;
[0014] vL CDR-L2 has the amino acid sequence shown in SEQ ID NO: 9; and
[0015] vL CDR-L3 has the amino acid sequence shown in SEQ ID NO: 10.
[0016] In the implementation scheme, the full-length anti-tau antibody comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 2 and a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 7.
[0017] In an embodiment, this disclosure provides a full-length humanized monoclonal IgG1 anti-tau antibody comprising two heavy chains and two light chains, wherein each of the heavy chains comprises an amino acid sequence as shown in SEQ ID NO:1, and each of the light chains comprises an amino acid sequence as shown in SEQ ID NO:6.
[0018] In an embodiment, this disclosure provides a full-length humanized monoclonal IgG1 anti-tau antibody comprising two heavy chains and two light chains, wherein each of the heavy chains comprises an amino acid sequence as shown in SEQ ID NO:16, and each of the light chains comprises an amino acid sequence as shown in SEQ ID NO:6.
[0019] In an embodiment, this disclosure provides a full-length humanized monoclonal IgG1 anti-tau antibody comprising two heavy chains and two light chains, wherein each of the heavy chains comprises an amino acid sequence as shown in SEQ ID NO:1 or SEQ ID NO:16, and each of the light chains comprises an amino acid sequence as shown in SEQ ID NO:6.
[0020] This document also provides compositions comprising the anti-tau antibody disclosed herein and a pharmaceutically acceptable carrier.
[0021] In its implementation, this disclosure provides a method for treating Alzheimer's disease, the method comprising administering an antibody according to this disclosure to a patient in need.
[0022] In its implementation, this disclosure provides a method for treating Alzheimer's disease, the method comprising administering to a patient in need a composition comprising an antibody of this disclosure and a pharmaceutically acceptable carrier. Attached Figure Description
[0023] Figure 1 The in vitro specificity of anti-tau antibody AbA for phosphorylated pT231 peptide is illustrated.
[0024] Figure 2 An example is shown of the in vitro binding of anti-tau antibody AbA to both phosphorylated T231tau and tau aggregates derived from brain tissue of AD patients in a dose-dependent manner.
[0025] Figure 3 An in vivo tau inoculation model according to this disclosure is illustrated.
[0026] Figure 4 An overview of the protocol for an in vivo tau inoculation model is provided, and the effect of the anti-tau antibody of this disclosure on hippocampal inoculation in an rTG4510 mouse inoculation model is illustrated.
[0027] Figure 5A A schematic diagram of an in vivo tau transmission model for tau pathology is provided.
[0028] Figure 5BPhotomicrographs are shown of neurons containing aggregated tau (AT100 IR) in the first and second synaptic brain regions following inoculation in the olfactory bulb in a tau propagation assay according to this disclosure. Following inoculation with AD lysate, the number of neurons containing AT100 IR increased in both a time-dependent and region-dependent manner, indicating that the pathology spread along the synaptic pathway.
[0029] Figure 6A Examples include tau aggregates (AT100 IR cells) in the medial thalamus and CA1 hippocampus two months after inoculation of AD lysates containing various concentrations of tau into the olfactory bulb.
[0030] Figure 6B The study illustrated the correlation between tau concentration in the injected lysate and the average number of neurons containing tau aggregates, suggesting that tau concentration in the donor sample promotes subsequent tau inoculation and spread in hTau mice.
[0031] Figure 7A An example of a study design for a hTau transmission efficacy study using anti-tau antibody chAbA is presented.
[0032] Figure 7B For example, two months after tau lysate was injected into the olfactory bulb, weekly intraperitoneal (ip) administration of chAbA significantly reduced the number of neurons containing AT100 IR tau aggregates in both the medial thalamus and CA1 hippocampus of female hTau mice compared with control IgG treatment.
[0033] Figure 8 For example, weekly intraperitoneal (ip) administration of chAbA significantly reduced the number of neurons containing aggregated tau (AT100 IR) compared to IgG-treated hTau mice and mice administered the N-terminal Pan-Tau antibody HJ8.5 (the mouse version of tilavonemab), cirrusammab, or IPN002. The three Pan-Tau antibodies did not affect the number of AT100 IR neurons in any of the brain regions analyzed.
[0034] Figure 9A Examples show that, compared with IgG-treated mice, weekly intraperitoneal (ip) administration of chAbA for 2 and 8 months significantly reduced the percentage of neurons containing aggregated tau in the CA1 hippocampus and medial thalamus, as measured by AT100IR.
[0035] Figure 9BFor example, weekly intraperitoneal (ip) administration of chAbA between 2 and 8 months post-vaccination resulted in a 54% and 87% reduction in the spread of tau pathology in the hippocampus and thalamus, respectively. Detailed Implementation
[0036] This article describes implementation schemes for anti-tau antibodies, particularly antibodies targeting pathological types of human tau. It is assumed that the antibodies of this disclosure specifically target tau pathological types that propagate across neurons, thereby inhibiting or delaying the spread of tau pathology between neurons through the synaptic cleft and slowing the accumulation of tau in the brain.
[0037] In the implementation scheme, AbA is a humanized monoclonal IgG1 antibody that binds to human tau. In the implementation scheme, AbA is a humanized monoclonal IgG1 antibody that binds to human tau peptide (pT231) phosphorylated at threonine 231.
[0038] In the implementation, the antibodies of this disclosure comprise variable regions and CDRs (complementarity-determining regions) identified according to rules developed in the art and / or by aligning sequences to a database of known variable regions. Methods for identifying these regions are described in the following literature: Kontermann and Dubel, eds., Antibody Engineering, Springer, New York, NY, 2001; and Dinarello et al., Current Protocols in Immunology, John Wiley and Sons Inc., Hoboken, NJ, 2000. For example, CDRs may be identified according to one of the protocols provided in Kabat et al. (1991), Sequences of Proteins of Immunological Interest (5th edition), US Dept. of Health and Human Services, PHS, NIH, NIH Publication No. 91-3242 (referred to herein as “Kabat”); or according to AbM (Oxford Molecular / MSI Pharmacopia) (referred to herein as “AbM”). AbM is available from the Abysis database at www.bioinf.org.uk / abs (maintained by AC Martin of the Department of Biochemistry & Molecular Biology, University College London).
[0039] In the implementation scheme, the anti-tau antibody AbA comprises CDRs as described in Table 1. Table 1. CDR (Kabat) of anti-tau antibody AbA
[0040]
[0041] In an embodiment, the anti-tau antibody of this disclosure comprises CDR-H1 having the amino acid sequence shown in SEQ ID NO: 3; CDR-H2 having the amino acid sequence shown in SEQ ID NO: 4; CDR-H3 having the amino acid sequence shown in SEQ ID NO: 5; CDR-L1 having the amino acid sequence shown in SEQ ID NO: 8; CDR-L2 having the amino acid sequence shown in SEQ ID NO: 9; and CDR-L3 having the amino acid sequence shown in SEQ ID NO: 10.
[0042] In some embodiments, the anti-tau antibody of this disclosure is an IgG isotype. In some embodiments, the anti-tau antibody of this disclosure is an IgG1 isotype, an IgG2 isotype, an IgG3 isotype, or an IgG4 isotype. In some embodiments, the anti-tau antibody of this disclosure is an IgG1 isotype. In some embodiments, the anti-tau antibody of this disclosure is an IgG2 isotype.
[0043] In the implementation scheme, the anti-tau antibody disclosed herein is a humanized antibody.
[0044] In the implementation scheme, the anti-tau antibody of this disclosure comprises a heavy chain variable region (vH CDR underlined and shown in order of appearance as SEQ ID NO: 3, 4 and 5) having the amino acid sequence shown as SEQ ID NO: 2:
[0045] EVQLVQSGAEVKKPGSSVKVSCKASGYTFT DYYMN WVRQAPGQGLEWIG VFYPHLGYTIYNQKFKG RATLTVDKSTSTAYMELSSLRSEDTAVYYCAS PYYYGSSSLDY WGQGTLVTVSS (SEQ ID NO: 2)
[0046] And the light chain variable regions having the amino acid sequence of SEQ ID NO: 7 (vL-CDR underlined and shown in order of appearance as SEQ ID NO: 8, 9 and 10 respectively):
[0047] DVQMTQSPSSVSASVGDRVTITC RSSQDLVESDADTYLH WYQQKPGKAPKLLIY KVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFC SQSTHVPFT FGQGTKVEIK (SEQ ID NO: 7).
[0048] In the implementation scheme, the anti-tau antibody of this disclosure comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 1 (variable regions are in bold; constant regions are in italics; CDRs are in regular text). Underlined And they are shown in order of appearance as SEQ ID NO: 3, 4 and 5 respectively.
[0049] EVQLVQSGAEVKKPGSSVKVSCKASGYTFT DYYMN WVRQAPGQGLEWIG VFYPHLGYTIYNQKFKG RATLTVDKSTSTAYMELSSLRSEDTAVYYCAS PYYYGSSSLDY WGQGTLVTVSSASTKGPSVFPLAPSSKSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDQLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHNHYTQKSLSLSPGK (SEQ ID NO: 1)
[0050] In the implementation scheme, the anti-tau antibody of this disclosure comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 16 (variable regions are in bold; constant regions are in italics; CDR). Underlined And they are shown in order of appearance as SEQ ID NO: 3, 4 and 5 respectively.
[0051] EVQLVQSGAEVKKPGSSVKVSCKASGYTFT DYYMN WVRQAPGQGLEWIG VFYPHLGYTIYNQKFKG RATLTVDKSTSTAYMELSSLRSEDTAVYYCAS PYYYGSSSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDQLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHNHYTQKSLSLSPG(SEQ ID NO: 16).
[0052] In the implementation scheme, the anti-tau antibody of this disclosure comprises a light chain having amino acid SEQ ID NO: 6 (variable region is bold; constant region is italic; CDR) Underlined And shown in order of appearance as SEQ ID NO: 8, 9 and 10 respectively):
[0053] DVQMTQSPSSVSASVGDRVTITC RSSQDLVESDADTYLH WYQQKPGKAPKLLIY KVSNRFS GVPSRFSGSGSGTDFTLTISSLQPEDFATYFC SQSTHVPFT FGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 6).
[0054] In the embodiments, the anti-tau antibody of this disclosure comprises two heavy chains and two light chains, each heavy chain having an amino acid sequence as shown in SEQ ID NO: 1, and each light chain having an amino acid sequence as shown in SEQ ID NO: 6.
[0055] In the embodiments, the anti-tau antibody of this disclosure comprises two heavy chains and two light chains, each heavy chain having an amino acid sequence as shown in SEQ ID NO: 16, and each light chain having an amino acid sequence as shown in SEQ ID NO: 6.
[0056] In the embodiments, the anti-tau antibody of this disclosure comprises two heavy chains and two light chains, each heavy chain having an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 16, and each light chain having an amino acid sequence as shown in SEQ ID NO: 6.
[0057] In embodiments, this disclosure provides one or more nucleic acids encoding any polypeptide as described herein. In embodiments, this disclosure provides polynucleotides encoding heavy chain polypeptides as described herein, such as polynucleotides encoding heavy chain polypeptides as shown in SEQ ID NO: 1 or SEQ ID NO: 16. In embodiments, this disclosure provides polynucleotides encoding light chain polypeptides as described herein, such as polynucleotides encoding light chain polypeptides as shown in SEQ ID NO: 6. In embodiments, this disclosure provides polynucleotides encoding (1) a heavy chain polypeptide as shown in SEQ ID NO: 1 or SEQ ID NO: 16 and (2) a light chain polypeptide as shown in SEQ ID NO: 6. Composition
[0058] The antibodies disclosed herein can be provided as compositions suitable for administration to subjects. In some embodiments, the antibody composition is a pharmaceutical composition comprising the antibody of this disclosure and a pharmaceutically acceptable carrier. How to use
[0059] This article provides implementation schemes for methods of treating Alzheimer's disease (AD), which include administering a therapeutically effective amount of the anti-tau antibody disclosed herein to a subject in need.
[0060] As used herein, the term "subject" refers to a person. The terms "person," "patient," and "subject" are used interchangeably in this document. Assay for assessing Tau inoculation and transmission
[0061] In the implementation plan, this document discloses assays for assessing tau transmission, and in particular in vivo assays for assessing tau transmission.
[0062] In the embodiments, the activity of the antibody of this disclosure can be evaluated in a tau inoculation assay. In the embodiments, this assay involves stereotactically injecting a lysate derived from brain tissue of a patient with Alzheimer's disease into the hippocampus of rTG4510 mice (2.5 µl, coordinates: AP: -1.9 mm; ML: -1.5 mm; DV: -1.6) (Santacruz K et al., Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005 Jul 15; 309(5733):476-81. doi: 10.1126 / science.1113694. PMID: 16020737; PMCID: PMC1574647). In the embodiments, this assay includes evaluating tau inoculation in the mouse brain, particularly by quantifying the percentage of the CA1 hippocampus area covered by tau aggregates. For example, in the embodiments, tau aggregates can be quantified in the CA1 hippocampus. Therefore, in the implementation scheme, the assays of this disclosure can be used to evaluate tau inoculation in the CA1 hippocampus.
[0063] In its implementation, this disclosure provides assays for assessing tau transmission, particularly in vivo assays for assessing tau transmission.
[0064] In one embodiment, the assay includes injecting a lysate derived from brain tissue of a patient with Alzheimer's disease into the olfactory bulb of an hTau mouse; in another embodiment, the mouse is an hTau mouse. In another embodiment, the assay includes evaluating tau propagation over time in the mouse brain, particularly by quantifying tau aggregates in synaptic connection regions of the brain. For example, in another embodiment, tau aggregates over time at tau inoculation sites in the olfactory bulb can be quantified. In another embodiment, tau aggregates can be evaluated in both first and second synaptic brain regions (e.g., the piriform cortex and entorhinal cortex; the medial thalamus and the CA1 hippocampus). Therefore, in another embodiment, the assay of this disclosure can be used to evaluate tau progression over time along synaptic pathways.
[0065] In one implementation, propagation to the first synapse (e.g., piriform cortex or entorhinal cortex) can be observed approximately 4 weeks after injection of the AD lysate. In another implementation, propagation to the second synapse (e.g., thalamus or hippocampus) can be observed approximately 6 weeks, 8 weeks, or 12 weeks after injection of the AD lysate. In yet another implementation, propagation to the second synapse (e.g., medial thalamus or CA1 hippocampus) is first observed approximately 6 weeks after AD lysate injection and becomes more robust approximately 8–12 weeks after injection.
[0066] In embodiments, the assay of this disclosure is performed in mice that do not express mouse tau. In embodiments, the assay is performed in mice that do not express aggregated tau even with aging. In embodiments, the assay is performed in mice that do not express mutant human tau. In embodiments, the assay is performed in mice that express both the 3R and 4R tau isotypes. In embodiments, the assay is performed in mice that express all six isotypes of the human MAPT gene (including both the 3R and 4R forms). For example, in embodiments, the assay is performed in hTau mice. hTau mice express the human tau isotype, but endogenous mouse tau is not detected. See, for example, Andorfer et al., “Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms,” J. Neurochemistry, 2003, 86, 582-590; Phillips et al., “Olfactory and Visuospatial Learning and Memory Performance in Two Strains of Alzheimer's Disease Model Mice—A Longitudinal Study,” PLoS One, 2001; 6(5): e195657. The full text of each reference is incorporated herein by reference.
[0067] In embodiments, the assay of this disclosure can be used to evaluate tau progression along synaptic pathways in hTau mice. In embodiments, the assay includes injecting a lysate derived from brain tissue of one or more patients with Alzheimer's disease into the olfactory bulb of an hTau mouse, and observing the accumulation of tau in neurons outside the olfactory bulb after injection of the AD lysate. For example, in embodiments, propagation to first synaptic brain regions (e.g., piriform cortex, entorhinal cortex) can be observed after approximately 4 weeks. In embodiments, propagation to second synaptic brain regions (e.g., CA1 hippocampus and medial thalamus) can be observed after approximately 6 weeks, and is more robust at approximately 8 and approximately 12 weeks after injection of the AD brain lysate.
[0068] In embodiments, this disclosure provides a method for evaluating the effect of an anti-tau compound on tau propagation, the method comprising injecting a lysate derived from brain tissue of a patient with Alzheimer's disease into the olfactory bulb of an hTau mouse. In embodiments, the method further comprises administering the anti-tau compound to the mouse after injection of the lysate. In embodiments, the anti-tau compound is an anti-tau antibody. In embodiments, tau is quantitatively aggregated in the olfactory bulb. In embodiments, tau is quantitatively aggregated in synaptic brain regions. For example, in embodiments, tau may be quantitatively aggregated in at least one region selected from the group consisting of the piriform cortex, medial thalamus, hippocampus, and entorhinal cortex. In embodiments, tau may be quantitatively aggregated in at least one first synaptic brain region selected from the group consisting of the piriform cortex and entorhinal cortex. In embodiments, tau may be quantitatively aggregated at a second synaptic brain region selected from the group consisting of the medial thalamus and CA1 hippocampus. In embodiments, the method may include comparing the amount of tau aggregated after administration of the anti-tau compound with the amount of tau aggregated using a reference compound. In embodiments, the reference compound is an IgG antibody that does not bind tau.
[0069] In one embodiment, the anti-tau compound may be administered at least approximately 1 day after lysate injection. In another embodiment, the anti-tau compound may be administered at least approximately 2 days after lysate injection. In another embodiment, the anti-tau compound may be administered at least approximately 3 days after lysate injection. In another embodiment, the anti-tau compound may be administered at least approximately 4 days after lysate injection. In another embodiment, the anti-tau compound may be administered at least approximately 5 days after lysate injection. In another embodiment, the anti-tau compound may be administered at least approximately 6 days after lysate injection. In another embodiment, the anti-tau compound may be administered at least approximately 7 days after lysate injection.
[0070] In the implementation scheme, tau is quantitatively accumulated in the mouse brain at least about 1 day, or at least about 2 days, or at least about 3 days, or at least about 4 days, or at least about 5 days, or at least about 6 days, or at least about 7 days after administration of the last dose of the antitau compound. In the implementation scheme, mouse brains are collected approximately 7 days after the last dose of the antitau compound. For example, in the implementation scheme, mice may be injected with a first dose of the antitau compound approximately 7 days after injection of AD brain lysate, followed by weekly doses of the antitau compound from week 2 to week 8, and mouse brains may be collected approximately 7 days after the week 8 dose.
[0071] In one embodiment, tau is quantitatively accumulated in the olfactory bulb. In another embodiment, tau is quantitatively accumulated in at least one synaptic junction region selected from the group consisting of the piriform cortex, entorhinal cortex, medial thalamus, and hippocampus. For example, in one embodiment, tau is quantitatively accumulated in at least one first synaptic junction region selected from the group consisting of the piriform cortex and entorhinal cortex. In another embodiment, tau is quantitatively accumulated in at least one second synaptic junction region selected from the group consisting of the hippocampus and thalamus. In another embodiment, tau is quantitatively accumulated in the olfactory bulb, at least one first synaptic junction region selected from the group consisting of the piriform cortex and entorhinal cortex, and at least one second synaptic junction region selected from the group consisting of the hippocampus and thalamus. In another embodiment, tau is quantitatively accumulated in the piriform cortex. In another embodiment, tau is quantitatively accumulated in the thalamus. In another embodiment, tau is quantitatively accumulated in the entorhinal cortex. In another embodiment, tau is quantitatively accumulated in the hippocampus. In another embodiment, tau is quantitatively accumulated in the olfactory bulb, piriform cortex, and thalamus. In the implementation plan, tau is quantitatively accumulated in the olfactory bulb, entorhinal cortex, and hippocampus.
[0072] In this embodiment, the aggregated tau is quantified by AT100 immunoreactivity quantification. AT100 is an anti-tau antibody that recognizes tau proteins phosphorylated at Thr212 and Ser214. In this embodiment, the aggregated tau is quantified by counting cell bodies that are immunoreactive to the AT100 anti-tau antibody (i.e., AT100 IR cell bodies).
[0073] In an embodiment, the method of this disclosure involves the injection of an AD brain lysate. In an embodiment, the lysate of this disclosure is a creatine-insoluble AD lysate. The creatine extraction of tau has been described, for example, in Guo et al., Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles, Journal Biol. Chem. Vol. 286, No. 17, 15317-15331 (2011); and Guo et al., Unique Pathological Tau Conformers from Alzheimer's brains transmit taupathology in nontransgenic mice, J. Exp. Med. 2016 Nov. 14; 213(12):2635-2654, the full text of which is incorporated herein by reference.
[0074] The tau propagation assay of this disclosure is correlated with the tau concentration in the AD lysate; that is, the tau concentration in the donor sample used to prepare the lysate promotes subsequent tau accumulation in hTau mice. In embodiments, the lysate of this disclosure has a concentration of at least about 250 nM, or at least about 350 nM, or at least about 450 nM, or at least about 550 nM, or at least about 650 nM. In embodiments, the lysis products of this disclosure have a tau concentration of at least about 750 nM, such as at least about 760 nM, or at least about 770 nM, or at least about 780 nM, or at least about 790 nM, or at least about 800 nM, or at least about 850 nM, or at least about 900 nM, or at least about 950 nM, or at least about 1000 nM, or at least about 1100 nM, or at least about 1200 nM, or at least about 1300 nM, or at least about 1400 nM, or at least about 1500 nM, or at least about 1600 nM, or at least about 1700 nM, or at least about 1800 nM, or at least about 1900 nM, or at least about 2000 nM. In one embodiment, the lysate has a tau concentration of about 750 nM to about 2500 nM, such as about 780 nM to about 2000 nM, or about 800 nM to about 2000 nM. In another embodiment, the lysate has a tau concentration of at least about 800 nM. In yet another embodiment, the tau in the AD lysate is primarily pathological tau protein, i.e., insoluble tau.
[0075] Figure 5AA schematic diagram of an in vivo tau propagation model for tau pathology according to this disclosure is provided. Lysates purified from brain tissue of AD patients were used to inoculate tau into the olfactory bulbs of female hTau mice expressing all six isotypes of normal human tau. Evidence of tau propagation was observed through the presence of neurons containing aggregated tau in brain regions synapsed with the olfactory bulb, including the piriform cortex and entorhinal cortex, which are first-synaptic brain regions. The piriform cortex projects to the medial thalamus (second-synaptic region), and entorhinal cortex neurons project to CA1 in the hippocampal structures (second-synaptic region). 6. Example
[0076] The following examples highlight certain features and characteristics of the implementation schemes described herein. Example 1: Generation of anti-tau antibodies
[0077] Mouse anti-tau antibody Ab1 was identified in CD-1 mice immunized with a mixture of the following six phosphopeptides derived from the human tau sequence: N-terminal and C-terminal KLH-conjugated pT231; N-terminal and C-terminal KLH-conjugated pS235; and N-terminal and C-terminal KLH-conjugated pT231 and pS235.
[0078] PT231 / PS235: 224 KKVAVVR P TPPK P SPSSAKSR 242
[0079] PS235: 224 KKVAVVR.TPPK P SPSSAKSR 242
[0080] PT231: 224 KKVAVVR P TPPK.SPSSAKSR 242
[0081] Immunotherapy libraries were constructed from tissues of immunized mice and screened using a phage panning strategy. The binding of phage exports to pT231, pS235, and pT231 / pS235 peptides was evaluated by ELISA.
[0082] The mouse antibody Ab1 was identified, which has a heavy chain sequence as shown in SEQ ID NO: 11 and a light chain sequence as shown in SEQ ID NO: 12, demonstrating specificity for phosphorylated T231 (pT231) peptides but no specificity for non-phosphorylated T231 peptides.
[0083] Ab1 was then humanized and CDR-engineered to eliminate potential liability and deamidation sites. This yielded a humanized antibody, AbA, having a heavy chain sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 16 and a light chain sequence as shown in SEQ ID NO: 6. AbA maintained its specificity for phosphorylated T231 peptide and also demonstrated a higher affinity for phosphorylated T231 peptide than the mouse Ab1 parent antibody.
[0084] To facilitate in vivo mouse testing, an AbA form was generated on the mouse IgG backbone. This antibody, chAbA, is a mouse IgG2a / k antibody having the heavy chain sequence shown in SEQ ID NO: 17 and the light chain sequence shown in SEQ ID NO: 18. chAbA maintains specificity for phosphorylated T231 peptide. Example 2: Anti-Tau antibody AbA exhibits specificity for phosphorylated (pT231) peptide.
[0085] The study aimed to examine the specificity of AbA for the tau protein-derived peptide KKVAVVRTPPKSPSSAK (SEQ ID NO: 13), which is either phosphorylated (pT231) or unphosphorylated at tyrosine 231. In this study, the peptide was biotinylated, phosphorylated (or unphosphorylated), and interacted with the bound antibody via ELISA.
[0086] ELISA was performed using a BioTek ELx405 plate washer (Agilent, Santa Clara, CA, USA) and 96-well Protein G plates (Thermo Fisher Scientific, Waltham, MA, USA) that had been washed once in 200 µL phosphate-buffered saline (PBS-T) containing 0.05% polysorbate 20. The plates were then incubated for 2 hours at ambient conditions on a shaker at 120 RPM with either AbA or control human IgG1-QL at a concentration of 1 µg / mL in 0.1% bovine serum albumin (BSA) in PBS-T. The plates were then washed three times with PBS-T and then incubated for 1 hour at ambient conditions on a shaker at 120 RPM with varying concentrations of N-terminal biotinylated phosphorylated T231 (SEQ ID NO: 13) and non-phosphorylated peptide (SEQ ID NO: 13) (range 1.6 ng / mL to 0.0002 ng / mL). The peptides were diluted three-fold in 0.1% BSA in PBS-T, ranging from 1.6 ng / mL to 0.002 ng / mL. After incubation, the plates were washed three times and incubated simultaneously at 120 RPM on a shaker with SA-HRP-40 (Fitzgerald Industries, Acton, MA, USA) diluted 1:6000 in 0.1% BSA in PBS-T for 1 hour under ambient conditions. After incubation, the plates were washed three times in PBS-T and developed with Super Slow ELISA TMB (MilliporeSigma, Burlington, MA, USA). The absorbance was read at 650 nM on a BioTek Synergy H1 microplate reader (Agilent) after 15 minutes.
[0087] The amount of biotinylated peptide bound by the antibody was determined by HRP-streptavidin detection, and the binding of AbA to tau-derived peptides was evaluated. Figure 1 Each sample was performed in triplicate in each run, and values from the three runs are expressed as the mean + / - SD. EC was calculated from each peptide binding ELISA. 50 The mean value from three different experiments was 0.06 ng / mL. In three independent runs, AbA was shown to selectively and dose-dependently bind phosphorylated T231 peptide, with an average EC50 of 0.06 ng / mL. 50 The concentration was 0.06 ng / mL. No binding to non-phosphorylated peptides was observed. The control mAb, human IgG1-QL, did not bind to any of these peptides.
[0088] Example 3: Preparation of human AD lysates from donor samples
[0089] Brain homogenates were generated from frontal cortical tissue of patients diagnosed with Alzheimer's disease (n=10). Using a Precellys Evolution tissue homogenizer (Bertin Technologies, Bretonneux, France), the tissues were homogenized in cold phosphate-buffered saline supplemented with 5 µL / mg (v / wt) of protease (MilliporeSigma, Burlington, MA, USA) and a phosphatase inhibitor (MilliporeSigma). After homogenization, the homogenate was rotated at 3000 xg for 5 minutes at 4°C, and the clear supernatant was collected. Equal volumes of the clear lysate from each patient were combined to produce a pooled lysate. The pooled AD lysate (n=13) was used in an in vitro immunodepletion assay (Example 4), and n=10 lysates were used in an in vivo inoculation assay (Example 5). The lysates were aliquoted and stored at -80°C until use. Example 4: In vitro activity of AbA antibody against pT231 peptide and human tau purified from brain tissue of AD patients.
[0090] Immunoexhaustion of AD lysates: The combined AD brain lysates (n=13) were then rotated at 3000 xg for the immunoexhaustion assay. AbA or allotype control human IgG1-QL antibody diluted 3-fold in the range of 100 nM to 0.01 nM was incubated with Protein G magnetic beads (Thermo Fisher Scientific) for 30 minutes. The antibody-coated magnetic beads were then incubated with the combined human AD lysates prepared as described in Example 3 above at a concentration of 100 nM tau in a HulaMixer sample under ambient conditions. ™ Incubate at approximately 5 RPM for 1.5 hours on a Thermo Fisher Scientific centrifuge. After incubation, pulse the sample in a benchtop centrifuge and place it directly on a magnetic holder for 1 minute.
[0091] Collect immune-depleted lysates and use them for single-molecule array (Simoa) ® Tau aggregate assays evaluate tau aggregate levels. Simoa is a bead-based tau aggregate assay developed using anti-tau mAb HT7 (Thermo Fisher Scientific) and mouse Ab1. For the pT231 assay, mouse Ab1 is used as the capture antibody and HT7 mAb is used as the detection antibody. For the tau aggregate assay, HT7 mAb is used as both the capture and detection antibody. (Following the manufacturer's protocol (Quanterix)...) ®(Billerica, MA, USA) uses antibody-labeled beads and biotinylated detection antibodies. Recombinant full-length P301L tau (SEQ ID NO: 14; Spillantini MG et al. Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau (Am J Pathol. Nov 1998; 153(5):1359-63) was purified using the method of Barghorn et al. (Purification of recombinant tau protein and preparation of Alzheimer-paired helical filaments in vitro. Methods Mol Biol. 2005; 299:35-51. Doi: 10.1385 / 1-59259-874-9:035.PMID: 15980594) and used to generate aggregates, such as Yanamandra et al. (Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron.) October 16, 2013; 80(2):402-414. doi: 10.1016 / j.neuron.2013.07.046) describes the production of hyperphosphorylated tau in SF9 cells (SEQ ID NO: 15; Tepper et al. Oligomer formation of tau protein hyperphosphorylated in cells. J Biol Chem. December 5, 2014; 289(49):34389-407. doi: 10.1074 / jbc.M114.611368). Hyperphosphorylated tau from SF9 cells was purchased as a cell paste containing recombinant protein from GenScript (GenScript ProBio, Piscataway, NJ, USA) and purified by Tepper's method (ibid.). The full-length P301L was used to purify the tau. Tau aggregates and SF9 cell-derived hyperphosphorylated tau were used as calibrators and included in each run to generate a standard curve.Simoa HD-X instrument, buffer, auxiliary beads, streptavidin β-galactosidase, and enzyme substrate halogen β-D-galactopyranoside were obtained from Quanterix. ® Perform the measurements according to the manufacturer's instructions. Dilute all samples in Tau calibration diluent (Quanterix) before performing Simoa.
[0092] Figure 2 This illustrates the dose-dependent in vitro binding of anti-tau antibody AbA to both phosphorylated taupT231 and tau aggregates derived from brain tissue of AD patients. Figure 2 As shown, unlike the IgG control, the AbA-magnetic bead complex dose-dependently depleted pT231 (where IC50) from AD lysates. 50 (2.64 nM) Figure 2 A) and tau aggregates (of which IC) 50 (3.68 nM) Figure 2 B). Calculation of IC from three independent immune exhaustion experiments. 50 Value. Using Simoa ® Ab1-HT7 and HT7-HT7tau aggregate assays measure the levels of pT231 and total tau aggregates. Values are expressed as mean + / - SD. Example 5: The role of anti-tau antibodies in an in vivo model inoculated with tau.
[0093] A tau inoculation model was developed in transgenic rTG4510 mice, in which tau was directly inoculated into the hippocampus using lysates. Figure 3 In short, protein lysates generated from the brain tissue of AD patients were stereotactically injected into the hippocampus of rTG4510 mice. Figure 3 A) Leads to the expression of tau (AT100 IR) that accumulates in the CA1 region of the hippocampus. Figure 3 B).
[0094] Transgenic rTG4510 mice were used in hippocampal inoculation studies (Santacruz 2005; 10.1126 / science.1113694). The original breeding mice were obtained with permission from Jackson Laboratory (Bar Harbor, ME, USA) at the Mayo Clinic (Rochester, MN, USA). Mice were housed at Charles River Laboratories (Sulzfeld, DE). Animal health and comfort were controlled by veterinarians. Mice were housed in groups in temperature and humidity-controlled chambers with a 12:12-hour dark / light cycle, with free access to water and food.
[0095] To evaluate the effect of treatment with antibody chAbA on tau seeding, as Figure 3 and Figure 4 exemplified, rTG4510 mice (6.5 to 7.5 weeks old) were pre-administered with the antibody (chAbA or IgG control) three times via intraperitoneal (i.p.) injection at doses X, Y and Z (where dose X < Y < Z) over a period of 10 days. chAbA represents the chimeric form of AbA on a mouse IgG backbone as described above. At 8-9 weeks of age, the animals were prepared for aseptic stereotaxic surgery, and a protein lysate derived from human AD brain (AD lysate, prepared as described in Example 2 above) was unilaterally injected into the hippocampus (2.5 µL, coordinates: AP: -1.9 mm; ML: -1.5 mm; DV: -1.6) using a Hamilton syringe (Hamilton, Reno, NV, USA). After recovering from surgery, the mice were returned to their home cages.
[0096] Three weeks later, the mice were euthanized, perfused with phosphate-buffered saline (PBS), and the brains were rapidly harvested. For the seeding study, the trimmed forebrains were drop-fixed in 10% formalin for 24 hours, then transferred to 70% ethanol:water. For the propagation study, the whole brains were drop-fixed in 10% formalin for 48 hours, then transferred to 70% ethanol:water. The brains were stored in 70% ethanol until all brains from the study were collected, to allow all samples to be processed simultaneously for paraffin embedding (Leica Biosystems, Wetzlar, DE).
[0097] After processing, four brains were embedded together in paraffin blocks in the coronal plane (Medite, Burgdorf, DE). Brains were randomized based on the test group, and paraffin blocks containing four randomized brains were generated. 4µm paraffin sections were prepared and processed on a Leica BOND Rx automated staining system (Leica Biosystems, Wetzlar, DE). In summary, slides were placed on the BOND RX, deparaffinized, rehydrated, and subjected to a series of pretreatments, including peroxide blocking, protein blocking (Abcam, Berlin, DE), treatment with 0.06µg / mL AT100 antibody (ThermoFisher Scientific, Darmstadt, DE) with citrate-buffered thermally induced antigen retrieval solution (Epitope Retrieval Solution 1 Bond, Leica), and detection based on diaminobenzidine (DAB) (Leica) and hematoxylin counterstaining (Leica). Digital images of stained tissue slides were collected using a P1000 scanner (3DHistec, Sysmex, Hamburg, DE).
[0098] To quantify Tau pathology induced by injected AD lysate and to test the therapeutic efficacy of antibodies, HALO was used. ™ The area quantification module in the image analysis software (Indica Labs, Albuquerque, NM, USA) analyzed three matched slices of each brain at the hippocampal level. For each slice, the CA1 region of the ipsilateral hippocampus was delineated. Using the software, a “threshold” was determined by an observer unaware of the animal’s treatment. The threshold was set so that positive brown DAB staining for AT100 immunoreactivity was recognized by the software and any background / nonspecific staining was excluded from the analysis. Once an appropriate threshold was set, the software measured the percentage of the region of interest (CA1 region) containing positive immunoreactivity to AT100. The AT100 IR area values for each animal were then plotted and analyzed in GraphPad Prism (Dotmatics, Boston, MA, USA).
[0099] Figure 4 The protocol for antibody pre-dose administration, seed injection, and tissue and serum collection was summarized, and AT100IR results were presented, illustrating the effect of anti-tau antibody chAbA on hippocampal inoculation in the rTG4510 inoculation model. Figure 4As shown, at doses Y and Z, chAbA significantly reduced tau pathology (measured as a percentage of the area of AT100IR in the CA1 region of the hippocampus) compared to IgG treatment. Three pre-dose administrations of chAbA at dose X to animals did not significantly reduce AT100IR in the CA1 region of the hippocampus. Example 6: In vivo Tau transmission assay Preparation of human creatine amide-insoluble tau AD lysate from donor sample
[0100] Donor brain tissue was weighed and homogenized three times using a Precellys Evolution homogenizer (Bertin Technologies, Bretonneux, FR) in TBS lysis buffer (50 mM TRIS, 150 mM NaCl, 20 mM NaF, 1 mM Na3VO4, 0.5 mM MgSO4 (pH 7.4)) containing protease and phosphatase inhibitors. After homogenization, the lysate was centrifuged at 27,000 xg for 20 min at 4 °C. The supernatant was conserved, and the resulting precipitate was resuspended in 1X salt / sucrose buffer (0.8 M NaCl, 10% sucrose, 10 mM TRIS HCl, 1 mM EGTA) and sonicated on ice. The sonicated sample was then centrifuged at 27,000 xg for 20 min at 4 °C. Combine the two supernatants and add an equal volume of 2X salt / sucrose buffer (1.6M NaCl, 20% sucrose, 20mM TRIS HCl, 2mM EGTA). Add 10% sarcodyl wash (in 1X salt / sucrose) to the combined supernatant to achieve a final sarcodyl concentration of 1% (w / v). Then, agitate the supernatant at ambient conditions for 1.5 hours. After agitation, centrifuge the sample at 250,000 xg for 90 minutes at 4°C. Resuspend the resulting precipitate in TBS, sonicate on ice, and centrifuge at 100,000 xg for 60 minutes at 4°C. Resuspend the resulting precipitate in sterile PBS, sonicate, and then centrifuge at 10,000 xg for 30 minutes at 4°C. The resulting supernatant is the sarcodyl-insoluble tau AD lysate for tau inoculation.
[0101] The aggregated tau species were quantified using a homogeneous time-resolved fluorescence (HTRF)-based tau aggregation assay kit (PerkinElmer-Cisbio, Waltham, MA, USA). The manufacturer's protocol was followed to ensure appropriate dilution of the donor and recipient fluorophore-labeled antibodies. The assay reaction (20 μL) was performed in 384-well microplates (Greiner Bio-One, Kremsmünster, AT), where samples were incubated with the fluorophore-labeled antibody at ambient temperature for 24 hours. Fluorescence signals were detected using a Cytation 5 (Agilent, Santa Clara, CA, USA) by excitation at 340 nm and emission at 620 nm and 665 nm. The relative FRET rate for each sample was determined by calculating the ratio of the two fluorescence intensities (665 / 620). Data were plotted in GraphPad Prism (Dotmatics), and statistical significance was compared between human AD and control brain lysates using one-way ANOVA.
[0102] Total tau levels were measured using the R-PLEX Human Total Tau Kit (Meso Scale Discovery, Rockville, MD) in a sandwich immunoassay. Biotinylated capture antibodies were diluted in coating diluent (MSD 100) and incubated on a shaker at ambient conditions for 1 hour. Stock solutions of the loading dye were prepared using nine aliquots of 4x laemmli buffer (Bio-Rad, Hercules, CA) and one aliquot of β-mercaptoethanol (Bio-Rad). For sample preparation, a 1:5 dilution of the sample was prepared using the loading dye and PBS, followed by vortexing and sedimentation using a benchtop microcentrifuge. The samples were then heated on a heating block at 95°C for 5 minutes and then placed on ice. The samples were diluted to 1:80,000 in MSD 101 and measured in duplicate. As recommended by the manufacturer, the R-plex human tau calibrator was prepared as a 7-point calibration curve starting at 5000 pg / mL and decreasing in a 4-fold dilution series down to 1.2 pg / mL. A blank was also included for background signal subtraction. After coating with the capture antibody for 1 hour, the plate was washed with 1x MSD Tris wash buffer at 150 μL / well. The calibrator and unknown were added in 25 μL / repeat, the plate was sealed with an adhesive plate sealer, and incubated on a shaker at ambient conditions for 1 hour. After 1 hour, the plate was washed with 150 μL / well of 1X MSD Tris wash buffer. 100x SULFO-tag detection antibody (Meso Scale Discovery) was diluted to 1x using MSD Diluent 101 and added to the plate at 50 μL / well. After incubation for 1 hour, the plate was washed with 1X MSD Tris wash buffer. In the final step, MSD Read Buffer T (4x) was diluted to 2X working solution in deionized water and added to the plate at 150 μL / well. Read the board immediately on the Meso Sector S600 (Meso Scale Discovery). Animals and Experimental Design
[0103] Female hTau mice (B6.Cg-Mapt Tg(MAPT)8cPdav / J, Jackson Laboratory, Bar Harbor, ME, USA) that were homozygous for the targeted allele and hemizygous for the transgene were used in these studies. Mice were provided at approximately 3 months of age and housed in five-animal-cage enclosures with free access to food and water using a 12:12-hour dark / light cycle.
[0104] Female hTau mice aged 4.5–5 months were prepared for sterile stereotactic surgery, and 2 μL of creatine lysate insoluble AD lysate was injected into the olfactory bulb using a Hamilton syringe (Hamilton). After recovery from surgery, the mice were returned to their cages. Intraperitoneal administration was initiated weekly, starting 7 days after seed injection (see [link to relevant documentation]). Figure 7A All experiments were conducted in full compliance with the Principles of Laboratory Animal Care (NIH Publication No. 86-23). Experiments conducted in the United States were fully compliant with AbbVie's Committee on Institutional Animal Care and Use (IACUC). All animal studies conducted in Germany were approved by the Government of Rhineland Palatinate (LandesuntersuchungsamtKoblenz, DE) and in accordance with European Parliament and Commission Directive 2010 / 63 / EU on the protection of animals for scientific purposes and the Regulation on the protection of animals for laboratory or scientific purposes (German implementation of EU Directive 2010 / 63). Animal studies were conducted at AAALAC accredited facilities, where veterinary care and supervision were provided to ensure appropriate animal care. Tissue processing and immunohistochemistry
[0105] At the appropriate time point, the mice were euthanized, perfused with phosphate-buffered saline (PBS), and the brains were quickly removed.
[0106] Following treatment, three brains from different treatment groups or time points were embedded together in a horizontally mounted paraffin block (Sakura Finetek, Torrance, CA, USA). Every fifth 5µm paraffin section was collected throughout the brain and mounted onto a glass slide. Twenty-five sections (every fifth section) from each block were stained for AT100 immunoreactivity using a BOND RX staining machine and a Refine assay kit (Leica). In short, the slides were deparaffinized, rehydrated, and placed on BOND RX (on which they underwent a series of pretreatments, including peroxide blocking, 5% donkey serum blocking (Leica)), and then incubated overnight in 0.006µg / mL of AT100 mouse monoclonal antibody against tau (Thermo Fisher Scientific, Waltham, MA, USA).
[0107] The slides were then returned to BOND RX, where they underwent a series of washes and were then incubated for 20 minutes in 2 µg / mL biotin-SP-conjugated F(ab')2 donkey anti-mouse IgG (H+L) secondary antibody (Jackson ImmunoResearch Labs, West Grove, PA, USA). Following further washing, the slides were incubated for 20 minutes in streptavidin / horseradish peroxidase (Leica), and immunoreactivity was visualized using diaminobenzidine (DAB; Leica) and counterstained with hematoxylin (Leica). AT100 Immunoreactivity Quantification
[0108] AT100 IR cells were counted by an observer unaware of the treatment or time points in matched sections across the entire range of the brain, including the olfactory bulb (8–10 sections / brain), piriform cortex (6–8 sections / brain), entorhinal cortex (8–10 sections / brain), CA1 hippocampus (10–12 sections / brain), and medial thalamus (9–11 sections / brain). Cell counts for each region were summed to obtain a number / brain region / mouse. Effect of htau concentration in AD lysate on tau accumulation in the olfactory bulb after inoculation (AT100 IR)
[0109] When purified human tau derived from brain tissue of various AD patients was injected into the olfactory bulb of female hTau mice, the level of tau accumulation along the brain regions of synaptic connections was correlated with the concentration of tau present in the lysate. Figure 4 A and Figure 4 B). In this study, lysates from individual AD donor brain tissue were prepared. Furthermore, lysates from multiple donors were mixed, and the amount of insoluble tau present in the samples was determined. Table 2: Cortical tissue from AD donors with different concentrations of tau
[0110]
[0111] The lysate was injected into the olfactory bulb of hTau mice. Two months after tau inoculation, neurons containing aggregated tau were visualized using AT100 IR and quantified in the olfactory bulb, piriform cortex, entorhinal cortex, medial thalamus, and CA1 hippocampus. Figure 6A Analysis showed that the concentration of tau in AD lysates was correlated with the level of tau pathology, with coefficients of variation ranging from 0.67 to 0.814. Figure 6B). Tau aggregates from the pooled samples also correlated with the results from individual samples, confirming that the levels of tau seeding and spreading in the model system depend on the concentration of insoluble tau present in the lysate injected into the olfactory bulb. This finding led to the standardization of the pooled AD lysate for subsequent studies to approximately 800 nM human tau protein. The efficacy of antibody treatment against tau transmission
[0112] A study was conducted to determine whether the chAbA anti-tau antibody could affect tau spreading and subsequent aggregation. The study design is as Figure 7A exemplified. Purified AD brain lysate was injected into the olfactory bulbs of 4.5-month-old female hTau mice; 7 days later, intraperitoneal (i.p.) administration of chAbA antibody at doses X, Y and Z (where X<Y<Z) was initiated. Weekly administration continued for 8 weeks after seeding with AD lysate.
[0113] Two months after pathological tau seeding, neurons containing tau aggregates were counted in the olfactory bulb as well as in the second synaptic brain regions, the CA1 hippocampus and the medial thalamus, as measured by AT100 IR. In the olfactory bulb, weekly intraperitoneal administration of chAbA did not affect tau pathology, indicating that this treatment had no effect on tau seeding. However, at the second synapse, weekly intraperitoneal administration of chAbA at all doses significantly reduced aggregated tau in both the CA1 hippocampus and the medial thalamus when administration was initiated seven days after seeding ( Figure 7B ). Analysis of these data shows that anti-tau chAbA antibody treatment can alter spreading without affecting tau seeding. Comparison of the efficacy of antibody treatment and N-terminal pan-tau antibodies against tau transmission.
[0114] A study was conducted to compare the efficacy of chAbA in the tau spreading model with the efficacy of N-terminal pan-tau targeting anti-tau antibodies previously tested in human clinical trials. The study design is identical to that Figure 7A exemplified in. Purified AD brain lysate was injected into the olfactory bulbs of 4.5-month-old female hTau mice; 7 days later, intraperitoneal (i.p.) administration of chAbA antibody, HJ8.5 (the mouse version of tilavonemab), the mouse version of semorinemab, and IPN002 was initiated. Weekly administration continued for 8 weeks after seeding in the olfactory bulb with AD lysate.
[0115] Two months after pathological tau inoculation, neurons containing tau aggregates were counted in the olfactory bulb, second synaptic brain region, CA1 hippocampus, and medial thalamus, as measured by AT100 IR. In the olfactory bulb, treatment with chAbA or N-terminal anti-tau antibody did not affect tau pathology, indicating that this treatment had no effect on tau inoculation. However, at the second synapse, weekly intraperitoneal (ip) administration of chAbA significantly reduced tau aggregates in both the CA1 hippocampus and medial thalamus compared to control IgG treatment and treatment with N-terminal reference antibody. Figure 8 When administration began seven days post-vaccination, cirenexumab, HJ8.5, and IPN002 did not significantly affect tau propagation in any of the second synaptic brain regions. Analysis of these data suggests that the tested chAbA, rather than the N-terminal anti-tau antibody, can alter tau propagation. Comparison of the efficacy of reference antibody treatment against tau transmission
[0116] A study was conducted to determine the efficacy of chAbA in a tau transmission model after weekly intraperitoneal administration for 8 months. Purified AD brain lysate was injected into the olfactory bulb of four-and-a-half-month-old female hTau mice; intraperitoneal (ip) administration of chAbA antibody began 7 days later. Administration continued weekly for 8 weeks (2M group) or 35 weeks (8M group) following inoculation with AD lysate.
[0117] Two and eight months after pathological tau inoculation, neurons containing tau aggregates were counted in the olfactory bulb, second synaptic brain region, CA1 hippocampus, and medial thalamus, as measured by AT100 IR. In the olfactory bulb, intraperitoneal (ip) administration of chAbA did not affect tau pathology at either time point, indicating that the treatment had no effect on tau inoculation. However, at the second synapse, compared with control IgG treatment, weekly intraperitoneal (ip) administration of chAbA significantly reduced the number of neurons containing aggregated tau in both the CA1 hippocampus and medial thalamus at both time points. Figure 9A Analysis of these data showed that, between 2 and 8 months after injection of AD lysates into the olfactory bulb, chAbA administration reduced the spread of tau pathology to the hippocampus and thalamus by 54%–87%, respectively. Figure 9B ).
[0118]
[0119]
[0120]
Claims
1. A full-length humanized IgG1 anti-tau antibody, wherein the full-length humanized IgG1 anti-tau antibody comprises a heavy chain variable region containing CDR-H1, CDR-H2, and CDR-H3, and a light chain variable region containing CDR-L1, CDR-L2, and CDR-L3, wherein: vH CDR-H1 has the amino acid sequence shown in SEQ ID NO: 3; vH CDR-H2 has the amino acid sequence shown in SEQ ID NO: 4; vH CDR-H3 has the amino acid sequence shown in SEQ ID NO: 5; vL CDR-L1 has the amino acid sequence shown in SEQ ID NO: 8; vL CDR-L2 has the amino acid sequence shown in SEQ ID NO: 9; and vL CDR-L3 has the amino acid sequence shown in SEQ ID NO:
10.
2. The full-length anti-tau antibody according to claim 1, wherein the heavy chain variable region has the amino acid sequence shown in SEQ ID NO: 2, and the light chain variable region has the amino acid sequence shown in SEQ ID NO:
7.
3. A full-length humanized monoclonal IgG1 anti-tau antibody, the full-length humanized monoclonal IgG1 anti-tau antibody comprising two heavy chains and two light chains, wherein each of the heavy chains comprises an amino acid sequence as shown in SEQ ID NO: 1, and each of the light chains comprises an amino acid sequence as shown in SEQ ID NO:
6.
4. A full-length humanized monoclonal IgG1 anti-tau antibody, the full-length humanized monoclonal IgG1 anti-tau antibody comprising two heavy chains and two light chains, wherein each of the heavy chains comprises an amino acid sequence as shown in SEQ ID NO: 16, and each of the light chains comprises an amino acid sequence as shown in SEQ ID NO:
6.
5. A pharmaceutical composition comprising the anti-tau antibody according to claims 1 to 4 and a pharmaceutically acceptable carrier.
6. A method for treating Alzheimer's disease, the method comprising administering a therapeutically effective amount of the anti-tau antibody according to claims 1 to 4 to a patient in need.
7. A method for treating Alzheimer's disease, the method comprising administering a therapeutically effective amount of the composition according to claim 5 to a patient in need.
